Viloxazine, a Non-stimulant Norepinephrine Reuptake Inhibitor, for the Treatment of Attention Deficit Hyperactivity Disorder: A 3 Year Update
Attention deficit hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder in childhood. Current treatment options for ADHD include pharmacological treatment (stimulants, non-stimulants, anti-depressants, anti-psychotics), psychological treatment (behavioral therapy with or without parent training, cognitive training, neurofeedback), and complementary and alternative therapies (vitamin supplementation, exercise). Central nervous system (CNS) stimulants are the primary pharmacological therapy used in treatment; however, these stimulant drugs carry a high potential for abuse and severe psychological/physical dependence. Viloxazine, a non-stimulant medication without evidence of drug dependence, is a selective norepinephrine reuptake inhibitor that has historically been prescribed as an anti-depressant medication. The extended-release (ER) form was approved by the US Food and Drug Administration (FDA) in April 2021 for the treatment of ADHD in pediatric patients aged 6-17 years. Phase 2 and 3 randomized control trials have demonstrated significant efficacy of viloxazine in improving ADHD symptoms versus placebo. Related to its long-standing use as an antidepressant, the safety profile and pharmacokinetics of viloxazine are well understood. Viloxazine appears to be a suitable alternative to current standard-of-care pharmacotherapy for ADHD, but the further investigation remains to be done in comparing its efficacy to that of current treatments.
1. Faraone SV, Asherson P, Banaschewski T, et al. Attention-deficit/hyperactivity disorder. Nat Rev Dis Primers. 2015;1(1):1-23. doi:10.1038/nrdp.2015.20
2. Mahone EM, Denckla MB. Attention-Deficit/Hyperactivity Disorder: A Historical Neuropsychological Perspective. J Int Neuropsychol Soc. 2017;23(9-10):916-929. doi:10.1017/s1355617717000807
3. Barkley RA, Peters H. The earliest reference to ADHD in the medical literature? Melchior Adam Weikard's description in 1775 of “attention deficit” (Mangel der Aufmerksamkeit, Attentio Volubilis). J Atten Disord. 2012;16(8):623-630. doi:10.1177/1087054711432309
4. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36(2):159-165. doi:10.1017/s003329170500471x
5. Jain R, Jain S, Montano CB. Addressing Diagnosis and Treatment Gaps in Adults With Attention-Deficit/Hyperactivity Disorder. Prim Care Companion CNS Disord. 2017;19(5):0-0. doi:10.4088/pcc.17nr02153
6. Cortese S, Coghill D. Twenty years of research on attention-deficit/hyperactivity disorder (ADHD): looking back, looking forward. Evid Based Mental Health. 2018;21(4):173-176. doi:10.1136/ebmental-2018-300050
7. Faraone SV, Glatt SJ. A Comparison of the Efficacy of Medications for Adult Attention-Deficit/Hyperactivity Disorder Using Meta-Analysis of Effect Sizes. J Clin Psychiatry. 2009;71(6):754-763. doi:10.4088/jcp.08m04902pur
8. ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2011;128(5):1007-1022. doi:10.1542/peds.2011-2654
9. Sonuga-Barke EJS, Brandeis D, Cortese S, et al. Nonpharmacological Interventions for ADHD: Systematic Review and Meta-Analyses of Randomized Controlled Trials of Dietary and Psychological Treatments. Am J Psychiatry. 2013;170(3):275-289. doi:10.1176/appi.ajp.2012.12070991
10. Visser SN, Danielson ML, Bitsko RH, et al. Trends in the Parent-report of Health Care Provider Diagnosed and Medicated ADHD: United States, 2003-2011. J Am Acad Child Adolesc Psychiatry. 2014;53(1):34-46.e2. doi:10.1016/j.jaac.2013.09.001
11. Rubia K, Overmeyer S, Taylor E, et al. Hypofrontality in attention deficit hyperactivity disorder during higher-order motor control: a study with functional MRI. Am J Psychiatry. 1999;156(6):891-896. doi:10.1176/ajp.156.6.891
12. Mostofsky SH, Cooper KL, Kates WR, Denckla MB, Kaufmann WE. Smaller prefrontal and premotor volumes in boys with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2002;52(8):785-794. doi:10.1016/s0006-3223(02)01412-9
13. del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2011;69(12):e145-e157. doi:10.1016/j.biopsych.2011.02.036
14. Pozzi M, Bertella S, Gatti E, et al. Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD). Expert Opin Emerg Drugs. 2020;25(4):395-407. doi:10.1080/14728214.2020.1820481
15. Catalá-López F, Hutton B, Núnez-Beltrán A, et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. Gluud C, ed. PLoS ONE. 2017;12(7):e0180355. doi:10.1371/journal.pone.0180355
16. Wolraich ML, Hagan JF Jr, Allan C, et al. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019;144(4):e20192528. doi:10.1542/peds.2019-2528
17. Barkley RA. A review of stimulant drug research with hyperactive children. J Child Psychol Psychiatry. 1977;18(2):137-165. doi:10.1111/j.1469-7610.1977.tb00425.x
18. Ahmann PA, Theye FW, Berg R, Linquist AJ, Van Erem AJ, Campbell LR. Placebo-controlled evaluation of amphetamine mixture-dextroamphetamine salts and amphetamine salts (Adderall): efficacy rate and side effects. Pediatrics. 2001;107(1):E10. doi:10.1542/peds.107.1.e10
19. Wender PH. Pharmacotherapy of attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry. 1998;59 Suppl 7:76-79.
20. Wilens TE, Spencer TJ, Biederman J. A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder. J Atten Disord. 2002;5(4):189-202. doi:10.1177/108705470100500401
21. Barkley RA, McMurray MB, Edelbrock CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics. 1990;86(2):184-192. doi:10.1542/peds.86.2.184
22. Abbruscato TJ, Trippier PC. DARK Classics in Chemical Neuroscience: Methamphetamine. ACS Chem Neurosci. 2018;9(10):2373-2378. doi:10.1021/ac schemneuro.8b00123
23. Perugi G, Pallucchini A, Rizzato S, Pinzone V, De Rossi P. Current and emerging pharmacotherapy for the treatment of adult attention deficit hyperactivity disorder (ADHD). Expert Opin Pharmacother. 2019;20(12):1457-1470. doi:10.1080/14656566.2019.1618270
24. Wang LJ, Shyu YC, Yuan SS, et al. Attention-deficit hyperactivity disorder, its pharmacotherapy, and the risk of developing bipolar disorder: A nationwide population-based study in Taiwan. J Psychiatr Res. 2016;72:6-14. doi:10.1016/j.jpsychires.2015.10.014
25. Wingo AP, Ghaemi SN. Frequency of stimulant treatment and of stimulant-associated mania/hypomania in bipolar disorder patients. Psychopharmacol Bull. 2008;41(4):37-47.
26. Castellanos FX, Giedd JN, Elia J, et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry. 1997;36(5):589-596. doi:10.1097/00004583-199705000-00008
27. DuPaul GJ, Barkley RA, McMurray MB. Response of children with ADHD to methylphenidate: interaction with internalizing symptoms. JAm Acad Child Adolesc Psychiatry. 1994;33(6):894-903. doi:10.1097/00004583-199407000-00016
28. Felt BT, Biermann B, Christner JG, Kochhar P, Harrison RV. Diagnosis and management of ADHD in children. Am Fam Physician. 2014;90(7):456-464.
29. Spencer T, Biederman J, Wilens T. Nonstimulant treatment of adult attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004;27(2):373-383. doi:10.1016/j.psc.2003.12.001
30. Qelbree (Viloxazine Extended-Release Capsules) [prescribing information]. Rockville, MD: Supernus Pharmaceuticals, Inc.; 2021.
31. Findling RL, Candler SA, Nasser AF, et al. Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status. CNS Drugs. 2021;35(6):643-653. doi:10.1007/s40263-021-00825-w
32. National Center for Biotechnology Information. PubChem Compound Summary for CID 5666, Viloxazine. Accessed May 6, 2022. https://pubchem.ncbi.nlm.nih.gov/compound/Viloxazine
33. Goldman LS, Genel M, Bezman RJ, Slanetz PJ, for the Council on Scientific Affairs AMA. Diagnosis and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. JAMA. 1998;279(14):1100-1107. doi:10.1001/jama.279.14.1100
34. Faraone SV, Gomeni R, Hull JT, et al. A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry. Published online September 28, 2021. doi:10.1007/s00787-021-01877-5
35. Faraone SV, Gomeni R, Hull JT, et al. Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials. Pediatr Drugs. 2021;23(6):583-589. doi:10.1007/s40272-021-00470-2
36. Lamb YN. Viloxazine: Pediatric First Approval. Pediatr Drugs. 2021;23(4):403-409. doi:10.1007/s40272-021-00453-3
37. Yu C. Metabolism and in vitro drug-drug interaction assessment of viloxazine. Xenobiotica. 2020;50(11):1285-1300. doi:10.1080/00498254.2020.1767319
38. Cutler AJ, Mattingly GW, Jain R, O'Neal W. Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agents. CNS Spectr. 2020;27(2):199-207. doi:10.1017/s1092852920001984
39. Yu C, Garcia-Olivares J, Candler S, Schwabe S, Maletic V. New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020;12:285-300. doi:10.2147/jep.s256586
40. Faison SL, Fry N, Adewole T, et al. Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Methylphenidate in Healthy Adults. Clin Drug Investig. 2021;41(2):149-159. doi:10.1007/s40261-020-00992-6
41. Wang Z, Kosheleff AR, Adeojo LW, et al. Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN-812 (Viloxazine Extended-Release) Pharmacokinetics in Healthy Adults. Clin Pharmacol Drug Dev. 2021;10(11):1365-1374. doi:10.1002/cpdd.948
42. Nasser A, Gomeni R, Wang Z, et al. Population Pharmacokinetics of Viloxazine Extended-Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder. J Clin Pharmacol. 2021;61(12):1626-1637. doi:10.1002/jcph.1940
43. Faison SL, Fry N, Adewole T, et al. Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults. J Clin Psychopharmacol. 2021;41(2):155-162. doi:10.1097/jcp.0000000000001361
44. Johnson JK, Liranso T, Saylor K, et al. A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD. J Atten Disord. 2020;24(2):348-358. doi:10.1177/1087054719836159
45. Faraone SV, Gomeni R, Hull JT, et al. Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials. Psychiatry Res. 2021;296:113664. doi:10.1016/j.psychres.2020.113664
46. Nasser A, Liranso T, Adewole T, et al. A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children. Clinical Therapeutics. 2020;42(8):1452-1466. doi:10.1016/j.clinthera.2020.05.021
47. Nasser A, Liranso T, Adewole T, et al. A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD. Psychopharmacol Bull. 2021;51(2):43-64.
48. Nasser A, Liranso T, Adewole T, et al. A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder. J Clin Psychopharmacol. 2021;41(4):370-380. doi:10.1097/jc p.0000000000001404
49. Nasser A, Liranso T, Adewole T, et al. Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial. Clinical Therapeutics. 2021;43(4):684-700. doi:10.1016/j.clinthera.2021.01.027
50. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The Worldwide Prevalence of ADHD: A Systematic Review and Metaregression Analysis. Am J Psychiatry. 2007;164(6):942-948. doi:10.1176/ajp.2007.164.6.942